Taysha Gene Therapies Inc. (NASDAQ: TSHA) closed the session at $25.00 after trading 0.63 million shares on Monday. Taysha Gene stock posted a positive performance of 25.06% in the last week and gained nearly 17.98% on 04/12/21.
The public currently owns 34.52M shares of TSHA stock, and there are 22.01M available shares. TSHA stock rocketed after exclusive world-wide rights to a clinical-stage gene therapy program were acquired.
The rights were acquired for what?
Taya Gene is being credited with spearheading research to eliminate monogenic CNS diseases. As a medical device company with a singular focus on curing diseases, TSHA strives to quickly translate its treatments from bench to bedside. Team members at TSHA have proven experience in developing and commercializing gene therapy drugs.
TSHA partnered with the world-class UT Southwestern Gene Therapy Program to build a comprehensive gene therapy pipeline aimed at working with both rare and widespread indications. The TSHA team leverages its fully integrated platform to search for potential cures with a goal of dramatically improving patients’ lives.
Taysha Gene yesterday announced there had been a deal reached on the exclusive worldwide rights to a clinical-stage AAV9 gene therapy program. Now referred to as TSHA-120, the gene therapy program is to treat giant axonal neuropathy (GAN).
In collaboration with a leading patient advocacy group seeking treatments and cures for GAN, the National Institutes of Health (NIH) is conducting the clinical trial.
How will the TSHA proceed?
Currently, a clinical trial whose purpose is to treat GAN with the intrathecal dose of TSHA-120 is currently underway. In order to treat GAN, Taysha Gene (TSHA) has received FDA designation for TSHA-120 as an orphan drug and rare pediatric disease.